Another study demonstrated that in high-grade prostate adenocarcinomas, 46% of them showed higher nuclear HIF1α immunostaining, and 89% expressed higher levels of VEGF [63]. The gene discussed is HIF1A; the disease is prostate adenocarcinoma.